Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMLM26- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial - The Master Protocol

Next Previous
Search
Trial Profile

AMLM26- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial - The Master Protocol

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Cedazuridine/decitabine (Primary) ; Gilteritinib (Primary) ; Ivosidenib (Primary) ; Revumenib (Primary) ; Sabatolimab (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms INTERCEPT

    • Most Recent Events

    • 07 Dec 2024 Initial result (as of the latest data cutoff, n=14) presented in the Syndax Pharmaceuticals Media Release.
    • 07 Dec 2024 According to a Syndax Pharmaceuticals media release, Initial result data from this trial were presented at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, December 7-10, 2024.
    • 05 Nov 2024 According to a Syndax Pharmaceuticals media release, Preliminary results from the first eight mNPM1 patients treated with revumenib will be presented at the upcoming 66th ASH Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top